Trial Profile
Phase I Study of Intratumoral CAVATAK (Coxsackievirus A21) and Pembrolizumab in Subjects With Advanced Melanoma (VLA-011 CAPRA)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 May 2021
Price :
$35
*
At a glance
- Drugs Gebasaxturev (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CAPRA
- Sponsors Viralytics
- 10 Apr 2021 Updated results presented at the 112th Annual Meeting of the American Association for Cancer Research
- 14 Jan 2020 Status changed from active, no longer recruiting to completed.
- 19 Jun 2019 Planned End Date changed from 10 Nov 2020 to 30 Dec 2019.